Simpler Grants.gov #360534

NCI Grant for Advanced Development and Validation of Cancer Research Technologies

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), is inviting grant applications to support the advanced development and validation of innovative technologies for cancer research. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Purpose: - Support R33-stage projects for emerging technologies that enable novel targeting, probing, analysis, handling, or quality control of biospecimens in cancer research - Technologies must address significant needs in cancer biology, early detection, diagnosis, treatment, control, epidemiology, or health disparities - Requirements: - Projects must focus on new technological capabilities, not just new applications of existing technologies - Technologies should be ready for rigorous validation and further development to encourage adoption by the research community - Only projects with feasibility gaps already overcome are eligible - Funding: - Total estimated program funding: $4,500,000 - Individual awards: $50,000 to $300,000 - No specific OEMs, vendors, or commercial products are named, as this is a research grant opportunity - Notable Exclusions: - Projects that merely apply existing technologies to new questions are not eligible - Place of Performance: - National Institutes of Health (federal office)

Description

The National Cancer Institute (NCI) is soliciting grant applications for exploratory research projects focused on the development and validation of emerging technologies with novel capabilities for targeting, probing, analyzing, handling, or quality control of biospecimens used in basic or clinical cancer research. The solicitation targets R33 applications where major feasibility gaps have been overcome but further development and validation are needed to encourage adoption by the research community. The technologies should accelerate or enhance research in cancer biology, early detection, clinical diagnosis, treatment, control, epidemiology, or address cancer health disparities, with a focus on cancer applications. Projects applying existing technologies with novelty only in the biological or clinical target are not appropriate. This funding opportunity is part of the NCI's Innovative Molecular Analysis Technologies (IMAT) Program.

View original listing